Clinical Trials in Huai'an, Jiangsu
18 recruiting
Showing 1–18 of 18 trials
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled204 locationsNCT06422143
Recruiting
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled280 locationsNCT06561386
Recruiting
Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled235 locationsNCT06551324
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled188 locationsNCT07028853
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 1Phase 2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC230 enrolled57 locationsNCT05319730
Recruiting
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
Crohn DiseaseStricture; BowelIntestinal Stricture
Second Affiliated Hospital, School of Medicine, Zhejiang University239 enrolled8 locationsNCT05387031
Recruiting
Phase 2Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.226 enrolled53 locationsNCT06378138
Recruiting
Phase 2
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
APL
Shanghai Jiao Tong University School of Medicine30 enrolled5 locationsNCT05881265
Recruiting
Not Applicable
Standardized Fecal Microbiota Transplantation for Crohn's Diseases
Inflammatory Bowel DiseaseCrohn's Disease (CD)
The Second Hospital of Nanjing Medical University800 enrolled2 locationsNCT01793831
Recruiting
Phase 2
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Marginal Zone Lymphoma
Huai'an First People's Hospital51 enrolled1 locationNCT06566807
Recruiting
Not Applicable
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
Acute Myeloid Leukemia
Yang Xiaotian50 enrolled1 locationNCT06536010
Recruiting
Not Applicable
Goal-directed Enteral Nutritional Perioperative Management
Esophagus Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences400 enrolled17 locationsNCT06510543
Recruiting
Not Applicable
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL
Primary Central Nervous System Lymphoma
Huai'an First People's Hospital30 enrolled1 locationNCT06445257
Recruiting
Not Applicable
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
Acute Myeloid Leukemia
Huai'an First People's Hospital34 enrolled1 locationNCT06328179
Recruiting
Phase 4
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
Alzheimer s Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.1,312 enrolled50 locationsNCT05908695
Recruiting
Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
Chronic Hepatitis B
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School4,500 enrolled5 locationsNCT05661786